Reimbursement practices for use of digital devices in atrial fibrillation and other arrhythmias: a European Heart Rhythm Association survey.

Since digital devices are increasingly used in cardiology for assessing cardiac rhythm and detecting arrhythmias, especially atrial fibrillation (AF), our aim was to evaluate the expectations and opinions of healthcare professionals in Europe on reimbursement policies for the use of digital devices (including wearables) in AF and other arrhythmias. An anonymous survey was proposed through announcements on the European Heart Rhythm Association website, social media channels, and mail newsletter. Two hundred and seventeen healthcare professionals participated in the survey: 32.7%, reported regular use of digital devices, 45.2% reported that they sometimes use these tools, 18.6% that they do not use but would like to. Only a minority (3.5%) reported a lack of trust in digital devices. The survey highlighted a general propensity to provide medical consultation for suspected AF or other arrhythmias detected by a consumer-initiated use of digital devices, even if time constraints and reimbursement availability emerged as important elements. More than 85% of respondents agreed that reimbursement should be applied for clinical use of digital devices, also in different settings such as post-stroke, post-cardioversion, post-ablation, and in patients with palpitations or syncope. Finally, 73.6% of respondents confirmed a lack of reimbursement fees in their country for physicians' consultations (tracings interpretation) related to digital devices. Digital devices, including wearables, are increasingly and widely used for assessing cardiac rhythm and detecting AF, but a definition of reimbursement policies for physicians' consultations is needed.

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: [e-mail].

Déclaration de conflit d'intérêts

Conflict of interest: G.B. received small speaker’s fees from Boston, Boehringer, Daiichi and Bayer, outside of the submitted work. E.S. has received institutional speaker/advisory fees from Bayer, Bristol-Myers Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme. F.G. received small speaker’s fees from Boston, Boehringer-Ingelheim, Bayer, Bristol-Meyer Squibb, Daiichi-Sankyo, outside of the submitted work. J.L.M. received speaker and consultancy fees from Medtronic, Microport, Sanofi, outside of the submitted work. D.D. received speaker fees from Abbott, Astra Zeneca, Bayer, Boston Scientific, Bristol-Myers Squibb, Medtronic, Microport, Pfizer, Zoll. S.B. is consultant for Medtronic, Boston Scientific, Microport, Zoll, and BMS. R.C.-A. received small speaker’s fees from Abbot, Johnson & Johnson, Boston Scientific, outside of the submitted work.